The present invention relates to basic polyene macrolide derivatives, characterized in that they comprise a basic polyene macrolide which is N-substituted by a 1-amino-1-deoxyketose group which in turn is substituted or unsubstituted, to a process for their preparation and to their use for obtaining drugs.
|
5. A compound which is 1-amino-1-deoxy-D-arabinoglucuronyl-amphotericin B of the formula: ##STR22## or its N-methylglucosamide salt, or its mixed oxalate and ammonium salt, where r1 is the macrocyclic part of amphotericin B.
6. A compound which is 1-amino-1-deoxy-D-arabinoglucuroamidyl-amphotericin B of the formula: ##STR23## or its N-methylglucosamine salt, or its mixed oxalate and ammonium salt, where r1 is the macrocyclic part of amphotericin B.
7. A compound which is 1-deoxy-1-amino-4,6-O-benzylidene-D-fructosyl-amphotericin B of the formula: ##STR24## or its N-methylglucosamine salt, or its mixed oxalate and ammonium salt, wherein r1 is the macrocyclic part of amphotericin B.
9. A compound of the formula: ##STR25## in which: r1 denotes the macrocyclic part of amphotericin B and
r2 represents a 1-amino-1-deoxyketose group substituted by substitutent(s) selected from the group consisting of (1) a divalent group of the formula ##STR26## replacing hydrogens of two different hydroxyl groups of the ketose, where r3 is selected from the group consisting of a hydrogen atom and a methyl group, and r4 is selected from the group consisting of a hydrogen, methyl, trichloromethyl, tert-butyl, propyl, benzyl, phenyl and phenyl substituted by a group selected from the group consisting of a methoxy, nitro and phosphate group, and (2) a monovalent group selected from the group consisting of methoxy, carboxyl, amide, nitrile, trihalogenomethyl, amine and mercapto group replacing a hydroxyl group of the ketose.
1. A basic polyene macrolide compound of the formula (I) ##STR17## in which: r1 denotes the macrocylic part of amphotericin B and
r2 represents a member selected from the group consisting of: (1) a structure of the formula: ##STR18## in which r3 is selected from the group consisting of a hydrogen atom and a methyl group, and r4 is selected from the group consisting of a hydrogen atom, a methyl, trichloromethyl, tert.-butyl, propyl, benzyl, phenyl group and a phenyl group substituted by a group selected from the group consisting of a methoxy, nitro and phosphate group, (2) - a structure of the formula: ##STR19## in which r5 and r6 are methyl groups, (3) - a structure of the formula: ##STR20## in which r7 is selected from the group consisting of a carboxyl, amide, nitrile and trihalogenomethyl group, and r8 is selected from the group consisting of a hydroxyl group, an amino group and a mercapto group, (4) - a structure of the formula: ##STR21## and a salt thereof, wherein said basic polyene macrolide compound is more soluble than the unsubstituted macrolide where r2 in formula I is hydrogen. 8. A fungicidal drug which comprises as the active principle in fungicidally effective amount a compound according to
10. The N-methylglucosamine salt of 1-deoxy-1-amino-4,6-O-benzylidene-D-fructosyl-amphotericin B of the formula: ##STR27## where r1 is the macrocylic portion of amphotericin B.
11. The mixed oxalate-ammonium salt of 1-deoxy-1-amino-4,6-O-benzylidene-D-fructosyl amphotericin B of the formula: ##STR28## where r1 is the macrocyclic part of amphotericin B.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The present invention relates to novel soluble and non-toxic derivatives of basic polyene macrolides and in particular to novel 1-amino-1-deoxyketoses. It also relates to a process for the preparation of these derivatives and to their use as drugs.
Polyene macrolides are a class of antifungal antibiotics which show a broad spectrum of activity in man against fungi and yeast pathogens. This is especially true of amphotericine B (AmB), which is an antifungal agent with a broad spectrum of fungistatic and fungicidal activity: Candida albicans, Coccidioides immitis, Sporotrichum, Cryptococcus neoformans, Histoplasma, Blastomyces, Rhizopus orizae, Aspergillus niger, etc. Despite the introduction of imidazoles, they still remain the most efficient drug against quite a number of conditions.
Furthermore, AmB has immunomodulating properties in mice and, to a certain degree, in man. It also enhances the activity of a certain number of anti-cancer drugs.
However, due to its macrocyclic nature and amphoteric character, the AmB which corresponds to the formula A below: ##STR1## is sparingly soluble in water and tends to form micelles in aqueous solution. Moreover, the toxicity of AmB towards animal cells and in particular kidney cells, lymphocytes and erythrocytes, imposes extreme precautions when using it clinically. This is especially the case for the treatment of deep-seated and systemic mycoses which have to be treated by intravenous administration.
These considerations have led many researchers to search for non-toxic and more soluble derivatives. Accordingly, a large number of derivatives have been produced which are modified either at the level of the acid function on C16 or at the level of the primary amine function on C3'. The work of the following authors may be mentioned in particular:
BRUZZESE et al., J. Pharm. sci. (1975), 64, 462: esterification of the carboxyl group;
FALKOWSKI et al., German Patent No. 3,013,631: amidation of the carboxyl group;
WRIGHT, U.S. Pat. No. 4,272,525: esterification of the carboxyl group and substitution of the amine on C3' by aminated acids;
SCHAFFNER and BOROWSKI Antib. & Chemo. (1961), II, 724: acetylation of the amine;
SIPOS and KESELSKI, U.S. Pat. No. 4,235,993: substitution of the amine group by a benzyl group;
KULBAKH et al., U.S. Pat. No. 4,007,166: formation of an N-methyl-D-glucaminemacrolide complex;
FALKOWSKI et al., U.S. Pat. No. 4,195,172, British Patent No. 1,387,187: reaction of glycol with the amine group.
Attempts have also been made to increase the solubility of amphotericine B by adding surface-active agents or by forming salts (European Patent 31,722). Unfortunately, all these attempts have resulted in derivatives which are unstable in solution or in derivatives which have lost their antibiotic properties.
FIG. 1 shows the UV spectrum of the compound AmB 12 F prepared in Example 14.
FIG. 2 shows the 13 CNMR spectra of AmB 12 F.
FIG. 3a shows the reverse phase HPLC spectra of the AmB derivative which is rearranged to produce rearranged AmB 12.
FIG. 3b shows the reverse phase HPLC spectra of the rearranged AmB 12.
FIG. 4 shows the stability of the compound AmB 20, produced in Examples 5 and 6, at different temperatures.
The present invention has therefore set itself the object of providing novel derivatives of basic polyene macrolides and especially of AmB which meet the requirements in practice better than the previously known derivatives by virtue of the fact that they are soluble, slightly or not at all toxic, that they retain the amphoteric character of AmB and that they are stable in aqueous medium. It has been known for a long time (Amadori, 1925) that glycosylamines are converted in acid medium into 1-amino-1-deoxyketoses. The same compounds can be obtained directly from a sugar and an amine in the presence of a suitable catalyst according to scheme B: ##STR2##
This so-called Amadori rearrangement has been described in more detail in Adv. Carbohydr. Chem. (1955), 10, 169. In their research into original derivatives which are soluble, have low toxicity and retain their stability in aqueous solution, the inventors noted that in the condensation reaction of a sugar with the primary amine function of the macrolide mycosamine (which has been attempted and carried out by various researchers), the nature of the condensed sugar played an essential role in the solubility and the stability of the derivatives obtained. Although the different sugars used are in theory all capable of forming a glycosylamine with AmB, it became apparent that the properties of solubility, stability and the biological properties depended on the ability of the glycosylamine thus formed to undergo an Amadori rearrangement.
The present invention relates to novel derivatives of basic polyene macrolides, characterized in that they comprise a basic polyene macrolide N-substituted by a 1-amino-l-deoxyketose group which in turn is substituted.
In the context of the present invention, a 1-amino-1-deoxyketose group is understood to mean any group resulting from the condensation of a reducing sugar which is substituted or unsubstituted with an amine function and having a characteristic beta-aminoketone functionality.
According to a preferred embodiment of the derivatives according to the invention, they correspond to the general formula I below: ##STR3## in which: R1 denotes the macrocyclic part of a polyene macrolide and
R2 represents:
a structure corresponding to the formula (a) below: ##STR4## in which R3 represents a hydrogen atom or a methyl group, and R4 represents a hydrogen atom, a methyl, trichloromethyl, tert.-butyl, propyl, benzyl or phenyl group, or a phenyl group substituted by one or more methoxy, nitro or phosphate groups, or, alternatively, R3 and R4 are the linking units of a cycloalkyl group, or, alternatively,
a structure b corresponding to the formula below: ##STR5## in which R5 and R6 are alkyl, aryl, or acyl groups, or, alternatively,
a structure corresponding to the formula c below ##STR6## in which R7 is an electron-withdrawing group, such as a carboxyl, ester, acyl, amide, nitrile or trihalogenomethyl group, or is a heterocyclic group, and R8 is a hydroxyl group, an amino group, or a mercapto group, or, alternatively,
a structure of the formula d below, in which R9, R10, R11 represent alkyl, acyl or aryl groups, and R12 represents a hydroxyl, amino or alkoxy group, ##STR7## or, alternatively, a disaccharide.
As the substituents for the substituted 1-amino-1-deoxyketose group there is present one or more of the following: a group of the formula ##STR8## replacing hydrogens of two different hydroxyl groups of the ketose, where R3 represents a hydrogen atom or a methyl group, and R4 represents a hydrogen, a methyl, trichloromethyl, tert-butyl, propyl, benzyl or phenyl group, or a phenyl group substituted by one or more methoxy, nitro or phosphate groups or, alternatively, R3 and R4 are the linking units of a cycloalkyl group, or an alkyl, aryl, or acyl group replacing a hydrogen of a hydroxyl group of the ketose, or an electron-withdrawing group, such as carboxyl, ester, acyl, amide, nitrile, trihalogenomethyl, heterocyclic, amino or mercapto group replacing a hydroxyl group of the ketose.
In particular the following substituents are exemplified: methyl-benzylidine, benzylidene, ethylidene, a methyl replacing hydrogen attached to oxygen and --N--acetyl, --COOH,--CONH2, and --NH2 attached to carbon and replacing --OH of the 1-amino-1-deoxyketose group.
Advantageously, the 1-amino-1-deoxyketoses according to the present invention, in contrast to the glycosylamines described in the abovementioned prior art which hydrolyze rapidly in water, are stable in neutral and acidic aqueous medium, and have
very satisfying solubilizing or dispersing properties in water
the biological properties of the starting glycosylamine
and a reduced cytotoxicity with respect to that of the starting glycosylamine.
The derivatives according to the invention can be obtained in the form of mixed salts whose nature depends on the catalyst chosen for the rearrangement or on the procedure of a step of substituting the mixed salt obtained by another salt, following the said rearrangement.
According to a preferred embodiment, the 1-amino-1-deoxyketoses according to the invention are in the form of salts of the Bronsted acid used for the rearrangement.
According to a particularly advantageous variation of this embodiment, the 1-amino-1-deoxyketoses are in the form of mixed salts of oxalate and ammonium.
According to another preferred embodiment of the invention, the 1-amino-1-deoxyketoses are in the form of N-methylglucosamine salts.
The present invention also relates to a process for the preparation of the derivatives of basic polyene macrolides according to the invention, characterized in that during a first step a glycosylamine is formed by condensation of the amine function of the macrolide with the anomeric carbon of a reducing sugar, and in that during a second step the glycosylamine obtained is rearranged in an anhydrous acidic medium to form a 1-amino-1-deoxyketose having a characteristic beta-amino-ketone functionality, and in that during a third step the 1-amino-1-deoxyketose obtained is separated from the reaction medium.
According to another embodiment of the process provided by the invention, the condensation step takes place with the exclusion of light, under inert atmosphere and in an anhydrous solvent, and at a temperature between 35°C and 50°C
According to yet another embodiment of the process provided by the invention, the rearrangement step is induced by the addition of a catalyst selected from the group comprising Bronsted acids, such as, for example, oxalic acid or acetic acid, and the so-called "active methylene" catalysts, such as, for example, ethyl malonate or 2,4-pentanedione.
According to a preferred variation of this embodiment, the separation of the derivative obtained is effected by adding an aqueous ammonium sulphate solution.
According to another preferred variation of this embodiment, the mixed salt obtained can advantageously be substituted by another salt. The mixed salt is suspended in methanol, an aqueous solution containing 1 to 3 equivalents of acid or base is then added volume by volume. By adding 3 volumes of butanol, the water can then be removed azeotropically and the product recovered in crystalline form.
The present invention also relates to novel drugs, characterized in that they contain as active component at least one of the macrolide derivatives according to the present invention.
Apart from the above arrangements, the invention comprises other arrangements which will become evident from the remainder of the description which follows.
However, it goes without saying that these preparation examples, and pharmacological tests and studies are given solely by way of an illustration of the subject of the invention, of which they represent no limitation whatsoever.
AmB is suspended in dimethylformamide (anhydrous, freshly distilled) with the exclusion of light, under an inert atmosphere and under strictly anhydrous conditions. 1.5 equivalents of 4,6-O-methylbenzylidene-D-glucopyranose are added all at once with magnetic stirring. The temperature of the mixture is brought to 38° C., and stirring is continued for a period ranging from 3 hours to 12 hours. When the solution is entirely clear, the catalyst is added (one equivalent if it is a Bronsted acid, such as oxalic acid, 10% by volume in the case of an "active methylene catalyst", and heating of the mixture is continued for 24 hours. The mixture is then cooled, and the 1-amino-1-deoxy-4,6-O-methylbenzylidene-D-fructosyl-AmB is precipitated by dropwise addition of a 10% ammonium sulphate solution in water with stirring. The precipitation is brought to completion by keeping the suspension at 4°C for 2 hours. A light yellow crystalline product is then recovered (after centrifugation and removal of the supernatant), which is washed twice with water (or an acetone/water mixture) so as to remove the excess starting carbohydrate and any trace of solvent.
The N-methylglucosamine salt of the carboxyl function of this derivative is prepared by suspending the final product of Example 1 in methanol and adding 2 equivalents of a polyhydroxylated base (N-methyl-glucosamine) dissolved in a volume of water equivalent to that of methanol. The mixture rapidly becomes clear, and 3 volumes of an entrainer (n-butanol) are then added. The mixture is evaporated under reduced pressure until the methanol and the water have been removed. The derivative slowly crystallizes in the remaining butanol, and the suspension is left at 4°C After centrifugation, the product is recovered, washed twice with butanol, then twice with ether. The derivative is finally dried under a high vacuum.
The procedure of obtaining this salt is similar to that used in Example 1, except that the carbohydrate coupled with the macrolide is 4,6di-O-methyl-D-glucopyranose.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 3 in methanol and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is 4,6-O-benzylidene-D-glucopyranose.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 5 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is 4,6-O-ethylidene-D-glucopyranose.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 7 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is 6-deoxy-6-N-acetyl-D-glucopyranose.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 9 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is D-glucurono-6,3-lactone.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 11 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is glucuronamide.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 13 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is 3-amino-3-deoxy-D-glucurono-6,3-lactam.
The N-methylglucosamine salt of the acid function of this derivative is prepared by suspending the final product of Example 15 in methanol, and then following the procedure described in Example 2.
The procedure used for preparing this salt is similar to that used in Example 1, except that the carbohydrate coupled to the macrolide is D-glucuronic acid. The product obtained is identical to that of Example 11.
The antibiotic efficiency was tested by the growth inhibition method in liquid medium (Sabouraud broth) in the presence of different concentrations of the derivatives studied.
A yeast suspension was cultivated in a broth in such a manner that about 1×102 cell/ml were obtained.
The tubes containing the different concentrations of antifungal substance were inoculated with the same amount of yeast cells, and were then incubated at 28°C for 18 hours with stirring. For each concentration of antifungal substance, two identical tubes were prepared.
The inhibition of fungal growth corresponding to the different concentrations was evaluated for each molecule by spectrophotometry at 620 nm and expressed in percent with respect to a reference solution without antifungal substance.
The antibiotic activity was tested by the diffusion method in agar-agar medium (Sabouraud agar-agar).
The efficiency of each molecule was determined by the size of the growth-inhibiting zone around a WHATMAN 3M paper disc impregnated with the antibiotic substance of a given concentration.
A suspension of Aspergillus spores in a broth was prepared, 0.2 ml of this suspension was used to inoculate at its surface an agar-agar medium which was solidified in such a manner that a homogeneous growth layer was obtained. After spreading, the WHATMAN 3M paper discs (diameter: 1 cm) were placed on the surface of the agar-agar, and then impregnated with 0.1 ml of the antibiotic substance at different concentrations.
The doses giving a 50% inhibition of the growth of the species S. cerevisiae, C. neoformans, P. orbiculare, C. albicans, C. albicans B 2630, and the doses giving a growth-inhibiting zone of the species A. flavus and A. fumigatus of 1 cm around a disc placed in the middle of the solid culture, determined in both cases using the derivatives 12, 17, 20, 22 and 23 of series G and F, are shown in Tables 1 and 1A below. These tables show that the AmB derivatives prepared according to the invention hence retain the antibiotic properties of the molecule from which they originated, namely AmB.
| TABLE 1 |
| ______________________________________ |
| ANTIFUNGAL IN VITRO ACTIVITY OF THE AmB |
| DERIVATIVES AGAINST DIFFERENT SPECIES OF |
| FUNGI: COMPARISON OF THE SALTS WITH THE |
| DIFFERENT AmB DERIVATIVES IC 50 in molarity* |
| Saccharomyces |
| Cryptoccocus |
| Pytirosporum |
| DERIVATIVES |
| cerevisiae neoformans orbiculare |
| ______________________________________ |
| FUGIZONE++ |
| N.D. 5 × 10-8 |
| 1.5 10-8 |
| AmB.cndot. |
| 5.4 × 10-7 |
| 8 × 10-8 |
| <10-8 |
| F series |
| AmB 12 1.1 × 10-6 |
| 6.5 × 10-8 |
| 9.6 × 10-8 |
| AmB 17 1.4 × 10-6 |
| 1.5 × 10-7 |
| 9 × 10-8 |
| AmB 20 1.1 × 10-6 |
| 4.5 × 10-8 |
| 1 × 10-7 |
| AmB 22 1.6 × 10-6 |
| 2.5 × 10-7 |
| 1.8 × 10-7 |
| AmB 23 1.6 × 10-6 |
| 1.5 × 10-7 |
| 7.6 × 10-8 |
| G series |
| AmB 12 6.2 × 10-7 |
| 8 × 10 8 |
| N.D. |
| AmB 17 8.6 × 10-7 |
| 6 × 10-8 |
| N.D. |
| AmB 20 1 × 10-6 |
| 6 × 10-8 |
| N.D. |
| AmB 22 1.2 × 10-6 |
| 1.2 × 10-7 |
| N.D. |
| AmB 23 1 × 10-6 |
| 1.7 × 10-7 |
| N.D |
| ______________________________________ |
| TABLE 1A |
| ______________________________________ |
| ANTIFUNGAL IN VITRO ACTIVITY OF THE AmB |
| DERIVATIVES AGAINST DIFFERENT SPECIES OF |
| FUNGI: COMPARISON OF THE SALTS WITH THE |
| DIFFERENT AmB DERIVATIVES IC 50 in molarity* |
| Candida Asper- |
| DERIVA- Candida albicans Aspergillus** |
| gillus** |
| TIVES albicans B 2630 flavus fumigatus |
| ______________________________________ |
| FUNGI- 1.9 × 10-8 |
| 8 × 10-8 |
| N.D N.D. |
| ZONE |
| AmB.cndot. |
| 8 × 10-8 |
| 3.5 × 10-7 |
| 5 × 10-5 |
| 5 × 10-5 |
| F series |
| AmB 12 9 × 10-8 |
| 2.4 × 10-7 |
| 3 × 10-4 |
| 8 × 10-5 |
| AmB 17 1.3 × 10-7 |
| N.D. 2 × 10-4 |
| 2 × 10-4 |
| Amb 20 8.5 × 10-8 |
| 1.5 × 10-7 |
| 1.5 × 10-4 |
| 2 × 10-4 |
| AmB 22 5.6 × 10-7 |
| N.D. 1.5 × 10-4 |
| 5 × 10-4 |
| AmB 23 4 × 10-7 |
| N.D. 6 × 10-4 |
| 2 × 10-4 |
| G series |
| AmB 12 1 × 10-7 |
| N.D. 9 × 10-5 |
| 1 × 10-4 |
| AmB 17 1.2 × l0-7 |
| N.D. 9 × 10-5 |
| 3.5 × 10-5 |
| AmB 20 1 × 10-7 |
| N.D. 6 × 10-4 |
| 1.3 × 10-4 |
| AmB 22 9 × 10-8 |
| N.D 9 × 10-5 |
| 1 × 10-4 |
| AmB 23 1 10-7 |
| N.D. 5 × 10-4 |
| 9 × 10-5 |
| ______________________________________ |
| Tables 1 and 1A |
| F series: Catalysis by oxalic acid, NMG salt |
| G series: Catalysis by oxalic acid, mixed ammonium and oxalate salt |
| *IC 50 = growthinhibiting concentration of 50% of the bacteria |
| .cndot. AmB dissolved in a 5% glucose solution |
| **concentration giving a growth inhibition of 1 cm around a disc in solid |
| medium |
| ++ registered trademark |
The toxic properties of the derivatives were studied on human and mouse red corpuscles and on lymph cells of peripheral blood from bone marrow and human thymus, on T and B spherical lymphocytes from mice and on two tumour strains: XG3 (mouse), Daudi (man).
All the solutions of the AmB derivatives according to the invention were prepared immediately before use by diluting 4 mg of substance in 100 μl of 5% glucose solution, and then, after 15 minutes protected from light, 100 μl of sterile distilled water are added, and the mixture is made up to stock solutions of 4 mg/ml with a 5% glucose solution. For comparative study of the effects of AmB, 4 mg of FUNGIZONE are diluted with 1 ml of 5% glucose.
The cells are prepared by placing 1 ml of a peripheral blood sample into a tube together with Ficollhypaque to remove the lymphocytes, and then centrifuging the mixture at 2000 rpm for 20 minutes. The remaining red corpuscles are recovered, washed once with 0.9% NaCl and then twice with 150 Mm KCl, 0.5 Mm tris-HCl, pH 7.4.
A 1.25% suspension is then prepared with 150 mM KCl solution, 0.5 mM tris-HCl, pH 7.4, and 150 μl thereof are distributed in wells along with 50 μl of each of the dilutions of the derivatives, plus a control well (5% glucose solution).
The cells are then incubated at 37°C in a steam cabinet for 1 hour 30.
To evaluate the cell lysis, haemoglobin is essayed by removing 100 μl of the supernatant in each well and diluting the sample with 1 ml of distilled water.
The haemoglobin concentration is calculated by measuring the optical density at 540 nm and taking into account the absorption of the derivatives of amphotericine B.
LD 50 is the dose which leads to lysis in 50% of the erythrocytes (a control of 100% lysis is obtained with distilled water, and reference lysis of 0% is obtained with the 5% glucose solution).
The solutions of the amphotericine B derivatives are prepared similarly to those mentioned in paragraph B.1.
The cells are prepared by placing 20 ml of blood diluted to 1/2 with 0.9% NaCl into a tube together with 10 ml of Ficoll-hypaque, and the mixture is centrifuged at 2000 rpm for 30 minutes. The cell nuclei are recovered and washed twice with PBS buffer containing 5% of foetal calf serum.
The cells are prepared by suspending 1.14×106 cells/ml in RPMI 1640 containing 2.5% of foetal calf serum and by filling each well with 150 μl. 50 μl of each dilution of the derivatives are added and also one control (5% glucose solution).
The cells are then incubated in a steam cabinet at a CO2 concentration of 5% for 1 hour 30 at 37°C or at ambient temperature.
To evaluate the toxicity of the derivatives, a cell count in the presence of trypan blue is made, and the LD 50 (concentration of the derivative leading to a mortality of 50%) is calculated with respect to the control (5% glucose solution) for each concentration of each derivative.
Tables 2, 2A and 3, 3A below show that the derivatives prepared according to the invention are much less toxic than amphotericine B for human and mice cells, and this can vary from derivative to derivative. Table 4 represents a comparative in vitro study of the toxicity of AmB, of the non-rearranged derivative, and of the same rearranged derivative using different catalysts.
In conclusion, these studies show that the derivatives obtained according to the present invention retain the antibiotic properties of AmB and that their toxicity has been completely lost or has diminished considerably.
| TABLE 2 |
| ______________________________________ |
| IN VITRO TOXICITY OF THE AmB DERIVATIVES |
| FOR DIFFERENT MICE CELLS: COMPARISON OF |
| THE SALTS OF DIFFERENT AmB DERIVATIVES. |
| LD 50 in molarity |
| RED T LY. GL. B LY. GL. |
| DERIVATIVES |
| CORPUSCLES CELLS+ |
| CELLS+ |
| ______________________________________ |
| FUNGIZONE++ |
| 6 × 10-6 |
| 1.5 × 10-6 |
| 2 × 10-6 |
| F SERIE |
| AmB 12 2 × 10-5 |
| 1 × 10-5 |
| 1 × 10-5 |
| AmB 17 3 × 10-5 |
| 2 × 10-5 |
| 1.5 × 10-4 |
| AmB 20 1.2 × 10-4 |
| 1 × 10-4 |
| 1 × 10-4 |
| AmB 22 9 × 10-5 |
| 2 × 10-5 |
| 2 × 10-5 |
| AmB 23 1.2 × 10-5 |
| N.D N.D. |
| G SERIE |
| AmB 12 2 × 10-5 |
| N.D. N.D. |
| AmB 17 1 × 10-5 |
| N.D. N.D. |
| AmB 20 4 × 10-6 |
| N.D. N.D. |
| AmB 22 1 × 10-5 |
| N.D. N.D. |
| AmB 23 4 × 10-6 |
| N.D. N.D. |
| ______________________________________ |
| TABLE 2A |
| ______________________________________ |
| IN VITRO TOXICITY OF THE AmB DERIVATIVES |
| FOR DIFFERENT MICE CELLS: COMPARISON OF |
| THE SALTS OF DIFFERENT AmB DERIVATIVES. |
| LD 50 in molarity |
| DERIVATIVES THYMOCYTES X 63** |
| ______________________________________ |
| FUNGIZONE++ |
| 2 10-6 4 10-5 |
| F SERIE |
| AmB 12 4 × 10-6 |
| >1 × 10-3 |
| AmB 17 8 × 10-6 |
| >1 × 10-3 |
| AmB 20 8 × 10-6 |
| >1 × 10-3 |
| AmB 22 3.5 × 10-6 |
| >1 × 10-3 |
| AmB 23 3 × 10-6 |
| >1 × 10-3 |
| G SERIE |
| AmB 12 5 × 10-6 |
| 5 × 10-4 |
| AmB 17 5 × 10-6 |
| 1.5 × 10-4 |
| AmB 20 4 × 10-6 |
| 1.5 × 10-4 |
| AmB 22 5 × 10-6 |
| 4 × 10-4 |
| AmB 23 2.5 × 10-6 |
| 5 × 10-4 |
| ______________________________________ |
| F SERIES: catalysis by oxlaic acid, NMG salt |
| G SERIES: catalysis by oxlaic acid, mixed ammonium and oxalate salt |
| + ly. gl.: paraaortic and inguinal lymph glands |
| **X 63: mice lymphoma B |
| ++ registered trademark |
| TABLE 3 |
| ______________________________________ |
| IN VITRO TOXICITY OF THE AmB DERIVATIVES |
| FOR DIFFERENT HUMAN CELLS: COMPARISON OF |
| THE SALTS OF DIFFERENT AmB DERIVATIVES |
| LD 50 in molarity |
| RED BONE |
| DERIVATIVES |
| PBL CORPUSCLES MARROW |
| ______________________________________ |
| FUNGIZONE++ |
| 3.5 × 10-5 |
| 3 × 10-6 |
| 2 × 10-4 |
| F SERIE |
| AmB 12 >1 × 10-3 |
| 1 × 10-4 |
| >1 × 10-3 |
| AmB 17 >1 × 10-3 |
| 2 × 10-4 |
| >1 × 10-3 |
| AmB 20 >1 × 10-3 |
| 2 × 10-4 |
| 1 × 10-3 |
| AmB 22 >1 × 10-3 |
| 1 × 10-4 |
| 1 × 10-3 |
| AmB 23 8 × 10-5 |
| 5 × 10-5 |
| N.D. |
| G SERIE |
| AmB 12 4.6 × 10-5 |
| 3 × 10-5 |
| N.D. |
| AmB 17 1 × 10-5 |
| 5 × 10-5 |
| N.D. |
| AmB 20 3 × 10-5 |
| 8 × 10-5 |
| N.D. |
| AmB 22 3 × 10-5 |
| 5 × 10-5 |
| N.D. |
| AmB 23 8 × 10-6 |
| 1 × 10-6 |
| N.D. |
| ______________________________________ |
| TABLE 3A |
| ______________________________________ |
| IN VITRO TOXICITY OF THE AmB DERIVATIVES |
| FOR DIFFERENT HUMAN CELLS: COMPARISON OF |
| THE SALTS OF DIFFERENT AmB DERIVATIVES |
| LD 50 in molarity |
| DERIVATIVES THMOCYTES DAUDI** |
| ______________________________________ |
| FUNGIZONE++ |
| 6 × 10-5 |
| 2 × 10-5 |
| F SERIE |
| AmB 12 >3 × 10-4 |
| >1 × 10-3 |
| AmB 17 >3 × 10-4 |
| >1 × 10-3 |
| AmB 20 >3 × 10-4 |
| >1 × 10-3 |
| AmB 22 >3 × 10-4 |
| >1 × 10-3 |
| AmB 23 N.D. >1 × 10-3 |
| G SERIE |
| AmB 12 N.D. >3 × 10-4 |
| AmB 17 N.D. 3 × 10-4 |
| AmB 20 N.D. 5 × 10-4 |
| AmB 22 N.D. 7 × 10-4 |
| AmB 23 N.D. 3 × 10-4 |
| ______________________________________ |
| F SERIES: catalysis by oxlaic acid, NMG salt |
| G SERIES: catalysis by oxlaic acid, mixed ammonium and oxalate salt |
| **DAUDI: human lymphoma B |
| ++ registered trademark |
| TABLE 4 |
| ______________________________________ |
| IN VITRO TOXICITY OF THE AmB 12 DERIVATIVE |
| FOR HUMAN PBLS: |
| COMPARISON OF DIFFERENT CATALYSTS |
| ______________________________________ |
| DERIVATIVE LD 50 |
| FUNGIZONE++ |
| 3.5 × 10-5 |
| Uncatalyzed(a) |
| 8 × 10-5 |
| NMG salt |
| Ethyl malonate(b) |
| >1 × 10-3 |
| NMG salt |
| Oxalic acid(b) |
| >1 × 10-3 |
| NMG salt |
| Acetic acid(b) |
| 2 × 10-4 |
| NMG salt |
| ______________________________________ |
| (a) nonrearranged derivative |
| (b) catalyst used for the rearrangement |
| ++ registered trademark |
The UV spectra of the AmB derivatives according to the invention show that the polyene structure of AmB is retained.
FIG. 1 shows the UV spectrum of AmB 12 F by way of example.
The 13 C NMR spectra of the derivatives according to the invention confirm their Amadori structure.
The 13 C NMR spectra of AmB 12 F is shown by way of example in FIG. 2.
FIG. 3 shows the reverse phase HPLC spectra of rearranged AmB 12 (3b) and of the corresponding non-rearranged derivative (32).
AmB or the derivatives obtained are dissolved at ambient temperature in a 5% glucose solution up to saturation.
Under these conditions, AmB is insoluble.
The AmB 17 derivative is soluble up to a concentration of 20 mg/ml.
The AmB 20 derivative is soluble up to a concentration of 40 mg/ml.
The AmB 12 derivative is soluble up to a concentration of 150 mg/ml.
PAC C.3.a : in solutionThe decomposition of the derivatives over time is monitored by HPLC.
FIG. 4 shows the results obtained (percentage of the non-decomposed derivative) with a 2.5 mg/ml solution of AmB 20 at
□37°C
ambient temperature
4°C
C.3.b. as a powder
When the derivatives according to the present invention are maintained in the form of a powder, they remain stable for several months.
Seman, Michel, Nicolay, Jean F.
| Patent | Priority | Assignee | Title |
| 10246478, | Jun 12 2014 | SHIONOGI & CO , LTD | Polyene macrolide derivative |
| 10696707, | Jun 12 2014 | Shionogi & Co., Ltd. | Polyene macrolide derivative |
| 5942495, | May 17 1996 | BTG International Limited | Antibiotics |
| 6562796, | Jan 14 2000 | MIGENIX INC | Derivatives of polyene macrolides and preparation and use thereof |
| 7141660, | Feb 08 2000 | Sinvent AS | Genes encoding a nystatin polyketide synthase and their manipulation and utility |
| 7709231, | Feb 08 2000 | Sinvent AS | Genes encoding a nystatin polyketide synthase and their manipulation and utility |
| 7851183, | Feb 08 2000 | Sinvent AS | Genes encoding a nystatin polyketide synthase and their manipulation and utility |
| 9745335, | Jun 15 2012 | BLIRT S A | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application |
| Patent | Priority | Assignee | Title |
| 4195172, | Apr 22 1976 | Politechnika Gdanska; Instytut Przemyslu Farmaceutycznego | Salts of N-glycosyl derivatives of polyene macrolides, especially N-methylglucamine salts as well as the method of their preparation |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 06 1990 | NICOLAY, JEAN-FRANCOIS | Laboratoires Mayoly-Spindler | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 006856 | /0564 | |
| Oct 06 1990 | NICOLAY, JEAN-FRANCOIS | SEMAN, MICHEL | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 006856 | /0564 | |
| Nov 14 1990 | Laboratoires Mayoly-Spindler | (assignment on the face of the patent) | / | |||
| Nov 14 1990 | Seman; Michel | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Sep 30 1997 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Oct 27 1997 | ASPN: Payor Number Assigned. |
| Nov 16 2001 | M184: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Dec 07 2005 | REM: Maintenance Fee Reminder Mailed. |
| May 24 2006 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| May 24 1997 | 4 years fee payment window open |
| Nov 24 1997 | 6 months grace period start (w surcharge) |
| May 24 1998 | patent expiry (for year 4) |
| May 24 2000 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 24 2001 | 8 years fee payment window open |
| Nov 24 2001 | 6 months grace period start (w surcharge) |
| May 24 2002 | patent expiry (for year 8) |
| May 24 2004 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 24 2005 | 12 years fee payment window open |
| Nov 24 2005 | 6 months grace period start (w surcharge) |
| May 24 2006 | patent expiry (for year 12) |
| May 24 2008 | 2 years to revive unintentionally abandoned end. (for year 12) |